Monocytes in coronary artery disease and atherosclerosis: where are we now?

Angie Ghattas, Helen R. Griffiths, Andrew Devitt, Gregory Y.H. Lip, Eduard Shantsila

Research output: Contribution to journalArticle

Abstract

Despite improvements in interventional and pharmacological therapy of atherosclerotic disease, it is still the leading cause of death in the developed world. Hence, there is a need for further development of effective therapeutic approaches. This requires better understanding of the molecular mechanisms and pathophysiology of the disease. Atherosclerosis has long been identified as having an inflammatory component contributing to its pathogenesis, whereas the available therapy primarily targets hyperlipidemia and prevention of thrombosis. Notwithstanding a pleotropic anti-inflammatory effect to some therapies, such as acetyl salicylic acid and the statins, none of the currently approved medicines for management of either stable or complicated atherosclerosis has inflammation as a primary target. Monocytes, as representatives of the innate immune system, play a major role in the initiation, propagation, and progression of atherosclerosis from a stable to an unstable state. Experimental data support a role of monocytes in acute coronary syndromes and in outcome post-infarction; however, limited research has been done in humans. Analysis of expression of various cell surface receptors allows characterization of the different monocyte subsets phenotypically, whereas downstream assessment of inflammatory pathways provides an insight into their activity. In this review we discuss the functional role of monocytes and their different subpopulations in atherosclerosis, acute coronary syndromes, cardiac healing, and recovery with an aim of critical evaluation of potential future therapeutic targets in atherosclerosis and its complications. We will also discuss technical difficulties of delineating different monocyte subpopulations, understanding their differentiation potential and function.

LanguageEnglish
Pages1541-1551
Number of pages11
JournalJournal of the American College of Cardiology
Volume62
Issue number17
Early online date21 Aug 2013
DOIs
Publication statusPublished - 22 Oct 2013

Fingerprint

Coronary Artery Disease
Monocytes
Atherosclerosis
Acute Coronary Syndrome
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Salicylic Acid
Cell Surface Receptors
Hyperlipidemias
Infarction
Cause of Death
Immune System
Thrombosis
Anti-Inflammatory Agents
Pharmacology
Inflammation
Research

Bibliographical note

Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Keywords

  • atherosclerosis
  • inflammation
  • macrophages
  • monocyte subsets

Cite this

Ghattas, Angie ; Griffiths, Helen R. ; Devitt, Andrew ; Lip, Gregory Y.H. ; Shantsila, Eduard. / Monocytes in coronary artery disease and atherosclerosis : where are we now?. In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 17. pp. 1541-1551.
@article{76dc2603d8b44ed0be6fb54762aed57e,
title = "Monocytes in coronary artery disease and atherosclerosis: where are we now?",
abstract = "Despite improvements in interventional and pharmacological therapy of atherosclerotic disease, it is still the leading cause of death in the developed world. Hence, there is a need for further development of effective therapeutic approaches. This requires better understanding of the molecular mechanisms and pathophysiology of the disease. Atherosclerosis has long been identified as having an inflammatory component contributing to its pathogenesis, whereas the available therapy primarily targets hyperlipidemia and prevention of thrombosis. Notwithstanding a pleotropic anti-inflammatory effect to some therapies, such as acetyl salicylic acid and the statins, none of the currently approved medicines for management of either stable or complicated atherosclerosis has inflammation as a primary target. Monocytes, as representatives of the innate immune system, play a major role in the initiation, propagation, and progression of atherosclerosis from a stable to an unstable state. Experimental data support a role of monocytes in acute coronary syndromes and in outcome post-infarction; however, limited research has been done in humans. Analysis of expression of various cell surface receptors allows characterization of the different monocyte subsets phenotypically, whereas downstream assessment of inflammatory pathways provides an insight into their activity. In this review we discuss the functional role of monocytes and their different subpopulations in atherosclerosis, acute coronary syndromes, cardiac healing, and recovery with an aim of critical evaluation of potential future therapeutic targets in atherosclerosis and its complications. We will also discuss technical difficulties of delineating different monocyte subpopulations, understanding their differentiation potential and function.",
keywords = "atherosclerosis, inflammation, macrophages, monocyte subsets",
author = "Angie Ghattas and Griffiths, {Helen R.} and Andrew Devitt and Lip, {Gregory Y.H.} and Eduard Shantsila",
note = "Copyright {\circledC} 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2013",
month = "10",
day = "22",
doi = "10.1016/j.jacc.2013.07.043",
language = "English",
volume = "62",
pages = "1541--1551",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier",
number = "17",

}

Monocytes in coronary artery disease and atherosclerosis : where are we now? / Ghattas, Angie; Griffiths, Helen R.; Devitt, Andrew; Lip, Gregory Y.H.; Shantsila, Eduard.

In: Journal of the American College of Cardiology, Vol. 62, No. 17, 22.10.2013, p. 1541-1551.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Monocytes in coronary artery disease and atherosclerosis

T2 - Journal of the American College of Cardiology

AU - Ghattas, Angie

AU - Griffiths, Helen R.

AU - Devitt, Andrew

AU - Lip, Gregory Y.H.

AU - Shantsila, Eduard

N1 - Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2013/10/22

Y1 - 2013/10/22

N2 - Despite improvements in interventional and pharmacological therapy of atherosclerotic disease, it is still the leading cause of death in the developed world. Hence, there is a need for further development of effective therapeutic approaches. This requires better understanding of the molecular mechanisms and pathophysiology of the disease. Atherosclerosis has long been identified as having an inflammatory component contributing to its pathogenesis, whereas the available therapy primarily targets hyperlipidemia and prevention of thrombosis. Notwithstanding a pleotropic anti-inflammatory effect to some therapies, such as acetyl salicylic acid and the statins, none of the currently approved medicines for management of either stable or complicated atherosclerosis has inflammation as a primary target. Monocytes, as representatives of the innate immune system, play a major role in the initiation, propagation, and progression of atherosclerosis from a stable to an unstable state. Experimental data support a role of monocytes in acute coronary syndromes and in outcome post-infarction; however, limited research has been done in humans. Analysis of expression of various cell surface receptors allows characterization of the different monocyte subsets phenotypically, whereas downstream assessment of inflammatory pathways provides an insight into their activity. In this review we discuss the functional role of monocytes and their different subpopulations in atherosclerosis, acute coronary syndromes, cardiac healing, and recovery with an aim of critical evaluation of potential future therapeutic targets in atherosclerosis and its complications. We will also discuss technical difficulties of delineating different monocyte subpopulations, understanding their differentiation potential and function.

AB - Despite improvements in interventional and pharmacological therapy of atherosclerotic disease, it is still the leading cause of death in the developed world. Hence, there is a need for further development of effective therapeutic approaches. This requires better understanding of the molecular mechanisms and pathophysiology of the disease. Atherosclerosis has long been identified as having an inflammatory component contributing to its pathogenesis, whereas the available therapy primarily targets hyperlipidemia and prevention of thrombosis. Notwithstanding a pleotropic anti-inflammatory effect to some therapies, such as acetyl salicylic acid and the statins, none of the currently approved medicines for management of either stable or complicated atherosclerosis has inflammation as a primary target. Monocytes, as representatives of the innate immune system, play a major role in the initiation, propagation, and progression of atherosclerosis from a stable to an unstable state. Experimental data support a role of monocytes in acute coronary syndromes and in outcome post-infarction; however, limited research has been done in humans. Analysis of expression of various cell surface receptors allows characterization of the different monocyte subsets phenotypically, whereas downstream assessment of inflammatory pathways provides an insight into their activity. In this review we discuss the functional role of monocytes and their different subpopulations in atherosclerosis, acute coronary syndromes, cardiac healing, and recovery with an aim of critical evaluation of potential future therapeutic targets in atherosclerosis and its complications. We will also discuss technical difficulties of delineating different monocyte subpopulations, understanding their differentiation potential and function.

KW - atherosclerosis

KW - inflammation

KW - macrophages

KW - monocyte subsets

UR - http://www.scopus.com/inward/record.url?scp=84886078994&partnerID=8YFLogxK

UR - http://psp.sagepub.com/content/33/1/43

U2 - 10.1016/j.jacc.2013.07.043

DO - 10.1016/j.jacc.2013.07.043

M3 - Article

VL - 62

SP - 1541

EP - 1551

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -